Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03374475 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT03374475 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 140 participants.
The verdict
NCT03374475, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 \[HDRS17\], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 \[HAM-D6\]) differs across different levels of hyper-arousal status (characterized by Sleep parameters, ruminative response scale \[RRS\], Sleep and Worry visual analogue scale \[VAS\], quantitative electro-encephalography \[qEEG\], heart rate variability \[HRV\] and others).
Interventions
- DRUG Placebo
- DRUG JNJ-42847922 20mg
- DRUG JNJ-42847922 40mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2019-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03374475
The ClinicalTrials.gov registry entry for NCT03374475 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03374475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03374475 about?
NCT03374475 is a clinical study titled "A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder". The purpose of this study is to explore if the magnitude of treatment effect (JNJ-42847922; placebo) on symptoms of depression (as measured by Hamilton rating scale for depression-17 \[HDRS17\], Sleep item-adjusted HDRS17, Anxiety/somatization factor score and the 6-item subscale from HDRS17 \[HAM-D...
What is the current status of trial NCT03374475?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2018-01-05. Estimated completion is 2019-04-29.
What interventions are being tested in trial NCT03374475?
The interventions under investigation include: Placebo (DRUG), JNJ-42847922 20mg (DRUG), JNJ-42847922 40mg (DRUG).
Who is sponsoring clinical trial NCT03374475?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.